WuXi Biologics and Amicus Sign Exclusive Manufacturing Partnership
SHANGHAI and CRANBURY, N.J., Feb. 12, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Amicus Therapeutics ("Amicus") (Nasdaq: F...
WuXi Biologics and AC Immune to Establish an Exclusive Strategic Partnership
* AC Immune to draw on WuXi Biologics' expertise in manufacturing innovative New Biological Entities against CNS disorders including proprietary WuXiUP continuous manufacturing platform that can significantly reduce cost of biologics * AC Immune to gain access to WuXi Biologics' proprietary...
WuXi Biologics Congratulates Tychan on First-in-Class Monoclonal Antibody for Yellow Fever after Record 7 Months of Development
SHANGHAI, Dec. 13, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company that offers end-to-end solutions for biologics discovery, development and manufacturing, today congratulates its partner Tychan for dosing of first individual in ph...
WuXi Biologics Achieves Breakthrough Titer of 51g/L in Cell Culture Productivity
SHANGHAI, Dec. 12, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it has achieved a breakthrough in cell culture productivi...
Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million
SHANGHAI and OXFORD, the United Kingdom, Dec. 11, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing and Oxford BioTherapeutics Ltd. ("OBT"), a clini...
Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million
SHANGHAI and OXFORD, the United Kingdom, Dec. 10, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing and Oxford BioTherapeutics Ltd. ("OBT"), a cl...
WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics
SHANGHAI, Dec. 10, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced today a strategic collaboration with Brii Biosciences (Brii Bio), an...
WuXi Biologics Wins SCRIP Award for "Best Company in an Emerging Market"
SHANGHAI and LONDON, Dec. 6, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company that offers end-to-end solutions for biologics discovery, development and manufacturing, today announced that it has won the SCRIP Award in the category o...
WuXi Biologics Wins SCRIP Award for "Best Company in an Emerging Market"
SHANGHAI and LONDON, Dec. 6, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company that offers end-to-end solutions for biologics discovery, development and manufacturing, today announced that it has won the SCRIP Award in the category o...
WuXi Biologics Commenced Construction of the Largest Biomanufacturing Facility Using Single-Use Bioreactors in Ireland
SHANGHAI and DUNDALK, Ireland, Dec. 5, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that the construction of new biologics dru...
WuXi Biologics Selected as Forbes Asia's Best Under A Billion 2018
SHANGHAI and TOKYO, Nov. 29, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it has been selected as Forbes Asia'sBest Under...
WuXi Biologics and ABL Bio Enter an Exclusive Development and Clinical Manufacturing Partnership for Multiple Bispecific Antibodies
SHANGHAI and SEOUL, Nov. 28, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK, WuXi Bio), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and ABL Bio Corporation (ABL Bio), a privately-held South ...
WuXi Biologics Commenced Construction of 1.6 million sq. ft. Biologics Innovation Center in Shanghai
SHANGHAI, Nov. 22, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that construction of a global innovation center has commenced ...
WuXi Biologics' Chief Executive Officer Dr. Chris Chen to Serve on Board of Directors at ISPE and Delivered Keynote Speech at 2018 Annual Meeting
SHANGHAI, Nov. 7, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced Dr.Chris Chen, Chief Executive Officer of WuXi Biologics, has b...
WuXi Biologics Commenced Construction of 48,000L Biologics Commercial Manufacturing Center in Shijiazhuang
* The new Biologics Center will be one of the largest in northern China SHIJIAZHUANG, China, Oct. 31, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufac...
WuXi Biologics Congratulates Tychan on Completing Human Safety Studies for the First-in-Class Zika Virus Antibody in Record Speed
SHANGHAI, Oct. 29, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company that offers end-to-end solutions for biologics discovery, development and manufacturing, today congratulates its partner Tychan on successful completion of Phase-1 ...
CANbridge Pharmaceutical and WuXi Biologics Enter into Strategic Partnership for Rare Disease Therapeutics
BEIJING and SHANGHAI, Oct. 23, 2018 /PRNewswire/ -- CANbridge Pharmaceutical Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions inChina and other markets, and WuXi Biologics (2269. HK), a leading global open-access biologics technology ...
I-Mab Biopharma Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody(TM) Platform for Three Bispecific Antibody Programs
SHANGHAI, Sept. 26, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing and I-Mab Biopharma ("I-Mab"), a biotech company focusing exclusively on innov...
WuXi Biologics Appoints Harvard Professor David R. Liu to Scientific Advisory Board
SHANGHAI, Sept. 25, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced the appointment ofDavid R. Liu, Professor of Chemistry and Ch...
WuXi Biologics Appoints Harvard Professor David R. Liu to Scientific Advisory Board
SHANGHAI, Sept. 24, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced the appointment ofDavid R. Liu, Professor of Chemistry and Ch...
